Targeting pemphigus autoantibodies through their heavy-chain variable region genes

Journal of Investigative Dermatology

Volumn 127, Issue 7, 2007, Pages 1681-1691

  Payne, Aimee S ^a   Siegel, Don L ^a   Stanley, John R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTISERUM; AUTOANTIBODY; DESMOGLEIN 1; DESMOGLEIN 3; IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DESMOGLEIN 3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNIZATION; IMMUNOGLOBULIN HEAVY CHAIN GENE; KERATINOCYTE; PATHOGENICITY; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; SOMATIC MUTATION; STATISTICAL SIGNIFICANCE;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; CELL LINE; CELLS, CULTURED; DESMOGLEIN 1; DESMOGLEIN 3; GENE THERAPY; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULIN VARIABLE REGION; KERATINOCYTES; PEMPHIGUS;

EID: 34250659705     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700790     Document Type: Article

References (48)

1. Adderson EE, Shackelford PG, Quinn A, Carroll WL (1991) Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J Immunol 147:1667-74
2. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. New Engl J Med 355:1772-9
3. Alvarado-Flores E, Avalos-Diaz E, Diaz LA, Herrera-Esparza R (2001) Anti-idiotype antibodies neutralize in vivo the blistering effect of Pemphigus foliaceus IgG. Scand J Immunol 53:254-8
4. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T (2000) Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 105:625-31
5. Arevalo JH, Taussig MJ, Wilson IA (1993) Molecular basis of crossreactivity and the limits of antibody-antigen complementarity. Nature 365:859-63
6. Arin MJ, Engert A, Krieg T, Hunzelmann N (2005) Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 153:620-5
7. Ay J, Keitel T, Kuttner G, Wessner H, Scholz C, Hahn M et al. (2000) Crystal structure of a phage library-derived single-chain Fv fragment complexed with turkey egg-white lysozyme at 2.0 A resolution. J Mol Biol 301:239-46
8. Ban N, Escobar C, Hasel KW, Day J, Greenwood A, McPherson A (1995) Structure of an anti-idiotypic Fab against feline peritonitis virus-neutralizing antibody and a comparison with the complexed Fab. FASEB J 9:107-14
9. Barbas CFI, Burton DR, Scott JK, Silverman GJ (2001) phage display: a laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor
10. Barbas SM, Ditzel HJ, Salonen EM, Yang WP, Silverman GJ, Burton DR (1995) Human autoantibody recognition of DNA. Proc Natl Acad Sci USA 92:2529-33
11. Bhol KC, Ahmed AR (2002) Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from pemphigus vulgaris patient. Autoimmunity 35:87-91
12. Boggon TJ, Murray J, Chappuis-Flament S, Wong E, Gumbiner BM, Shapiro L (2002) C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 296:1308-13
13. Boucher G, Broly H, Lemieux R (1997) Restricted use of cationic germline V(H) gene segments in human Rh(D) red cell antibodies. Blood 89:3277-86
14. Bourgeois C, Bour JB, Aho LS, Pothier P (1998) Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Virol 72:807-10
15. Capon F, Bharkhada J, Cochrane NE, Mortimer NJ, Setterfield JF, Reynaert S et al. (2006) Evidence of an association between desmoglein 3 haplotypes and pemphigus vulgaris. Br J Dermatol 154:67-71
16. Chang TY, Siegel DL (1998) Genetic and immunological properties of phage-displayed human anti-Rh(D) antibodies: implications for Rh(D) epitope topology. Blood 91:3066-78
17. Ditzel HJ, Itoh K, Burton DR (1996) Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. J Immunol 157:739-49
18. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C (2004) Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 50:974-6
19. Futei Y, Amagai M, Sekiguchi M, Nishifuji K, Fujii Y, Nishikawa T (2000) Use of domain-swapped molecules for conformational epitope mapping of desmoglein 3 in pemphigus vulgaris. J Invest Dermatol 115:829-34
20. Goodyear CS, Silverman GJ (2003) Death by a B cell superantigen: in vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal toxin. J Exp Med 197:1125-39
21. Goodyear CS, Silverman GJ (2004) Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Natl Acad Sci USA 101:11392-7
22. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB et al. (2000) Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci USA 97:5399-404
23. Hacker-Foegen MK, Janson M, Amagai M, Fairley JA, Lin MS (2003) Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies. J Invest Dermatol 121:1373-8
24. Hoet RM, Pieffers M, Stassen MH, Raats J, de Wildt R, Pruijn GJ et al. (1999) The importance of the light chain for the epitope specificity of human anti-U1 small nuclear RNA autoantibodies present in systemic lupus erythematosus patients. J Immunol 163:3304-12
25. Ibrahim SM, Weigert M, Basu C, Erikson J, Radic MZ (1995) Light chain contribution to specificity in anti-DNA antibodies. J Immunol 155:3223-33
26. Ishii K, Harada R, Matsuo I, Shirakata Y, Hashimoto K, Amagai M (2005) In vitro keratinocyte dissociation assay forevaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris. J Invest Dermatol 124:939-46
27. Kawasaki H, Tsunoda K, Hata T, Ishii K, Yamada T, Amagai M (2006) Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphigus vulgaris blister formation. J Invest Dermatol 126:2621-30
28. Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA (2003) The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med 197:1501-10
29. Martel P, Gilbert D, Drouot L, Prost C, Raux G, Delaporte E et al. (2001) A polymorphic variant of the gene coding desmoglein 1, the target autoantigen of pemphigus foliaceus, is associated with the disease. Genes Immuni 2:41-3
30. Nagar B, Overduin M, Ikura M, Rini JM (1996) Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature 380:360-4
31. Newkirk MM, Rauch J, Mageed RA, Jefferis R, Posnett DN, Silverman GJ (1993) Restricted immunoglobulin variable region gene usage by hybridoma rheumatoid factors from patients with systemic lupus erythematosus and rheumatoid arthritis. Mol Immunol 30:255-63
32. Ohlin M, Owman H, Mach M, Borrebaeck CA (1996) Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol Immunol 33:47-56
33. Payne AS, Hanakawa Y, Amagai M, Stanley JR (2004) Desmosomes and disease: pemphigus and bullous impetigo. Curr Opin Cell Biol 16:536-43
34. Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y et al. (2005) Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 115:888-99
35. Qian Y, Clarke SH, Diaz LA (2006) Dissecting the autoreactive B cell repertoire in pemphigus vulgaris patients. J Invest Dermatol 126(Suppl 4):10 (abstract)
36. Rader C, Popkov M, Neves JA, Barbas CF III (2002) Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J 16:2000-2
37. Roark JH, Bussel JB, Cines DB, Siegel DL (2002) Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 100:1388-98
38. Roben P, Barbas SM, Sandoval L, Lecerf JM, Stollar BD, Solomon A et al. (1996) Repertoire cloning of lupus anti-DNA autoantibodies. J Clin Invest 98:2827-37
39. Rose DR, Przybylska M, To RJ, Kayden CS, Oomen RP, Vorberg E et al. (1993) Crystal structure to 2.45 A resolution of a monoclonal Fab specific for the Brucella A cell wall polysaccharide antigen. Protein Sci 2:1106-13
40. Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M (2001) Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol 167:5439-48
41. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grubel G et al. (1995) Structural basis of cell-cell adhesion by cadherins. Nature 374:327-37
42. Siegel DL (2001) Research and clinical applications of antibody phage display in transfusion medicine. Transfus Med Rev 15:35-52
43. Silberstein LE, Jefferies LC, Goldman J, Friedman D, Moore JS, Nowell PC et al. (1991) Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood 78:2372-86
44. Stanley JR (2003) Pemphigus. In: Fitzpatrick's dermatology in general medicine (Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds), New York: McGraw-Hill, 558-67
45. Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF III (2000) Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 275:36073-8
46. Tsunoda K, Iemura S, Nakagawa T, Natsume T, Amagai M (2006) Binding kinetic analysis of anti-desmoglein 3 monoclonal antibodies by surface plasmon resonance technology. J Invest Dermatol 126(Suppl 4):28 2006 (abstract)
47. Yeh SW, Cavacini LA, Bhol KC, Lin MS, Kumar M, Duval M et al. (2006) Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol 120:68-75
48. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78:3155-61